Publications by authors named "Claudio Lavarello"
Article Synopsis
- The study investigates how common temporomandibular disorders (TMD) are in adolescents with juvenile fibromyalgia syndrome (JFS) and looks for unique TMD characteristics linked to JFS.
- By using a specially designed questionnaire and clinical examination, researchers assessed TMD signs and symptoms in 30 JFS patients and 45 healthy controls, finding significantly higher reports of orofacial pain and TMJ tenderness in JFS patients.
- The findings suggest that TMD is prevalent in JFS, and indicators like TMJ hypermobility and orofacial pain are important for diagnosis, highlighting the need for a comprehensive approach to treatment for affected adolescents.
Introduction: Juvenile Sjögren's disease (jSjD) is a rare autoimmune disease characterized by exocrine gland involvement and systemic manifestations, including small vessel vasculitis and Raynaud's phenomenon (RP). We aimed to investigate the microvascular status in jSjD patients by nailfold videocapillaroscopy (NVC) and the potential correlations with clinical and serological features.
Methods: Clinical data from thirteen consecutive jSjD patients (11 females and 2 males), with a mean age of 16 ± 4 years, diagnosed before 16 years of age (mean age at diagnosis 12 ± 3) according to the 2016 American College of Rheumatology/EULAR criteria for adult SjD, were collected including age- and sex-matched healthy controls (HCs).
Objective: To investigate sleep quality in juvenile fibromyalgia syndrome (JFS) and its effect on the global burden of the disease.
Methods: Consecutive patients with JFS who performed full-night polysomnography (PSG) were included in this cross-sectional study. JFS-related symptoms, neuropsychiatric features, and sleep quality were assessed using self-report measures.
Article Synopsis
- - The study investigates the use of Prednisone (PDN) as a primary treatment for juvenile dermatomyositis (JDM) and seeks to establish evidence-based guidelines for tapering and discontinuing glucocorticoids (GC) in new JDM patients.
- - Children with new onset JDM were randomly assigned to receive PDN alone or with other immunosuppressive drugs (methotrexate or cyclosporine), with assessments made on their clinical remission status and the effectiveness of GC tapering.
- - Key findings suggest that significant reductions in disease indicators allow for the tapering of GC doses within the first six months, and factors such as age, response to treatment, and combination therapy are linked to